Genetic variants associated with glycemic response to treatment with dipeptidylpeptidase 4 inhibitors
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F20%3A10410902" target="_blank" >RIV/00216208:11130/20:10410902 - isvavai.cz</a>
Alternative codes found
RIV/00064203:_____/20:10410902 RIV/00023001:_____/20:00079677
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=3q2MP82xm-" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=3q2MP82xm-</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.2217/pgs-2019-0147" target="_blank" >10.2217/pgs-2019-0147</a>
Alternative languages
Result language
angličtina
Original language name
Genetic variants associated with glycemic response to treatment with dipeptidylpeptidase 4 inhibitors
Original language description
Aim: We examined associations of eight SNPs in/near seven candidate genes with glycemic response to 6 month treatment with DPP4 inhibitors. Patients & methods: 206 patients with type 2 diabetes (116 men and 90 women) were treated with sitagliptin or vildagliptin (both 100 mg/day) in combination with metformin or metformin/sulphonylurea over 6 months, and the reduction in glycated hemoglobin (HbA1c) was measured. Results: Rs6923761 in GLP1R was significantly associated with a reduction in HbA1c (adjusted p = 0.006). Homozygotes for the minor A allele had smaller reduction in HbA1c by 0.4% (4 mmol/mol) than the G allele carriers (p = 0.016). Conclusion: The missense variant rs6923761 in the GLP1R gene was associated with a smaller glycemic response to 6 month gliptin therapy in diabetic patients of central European origin. (C) 2020 Future Medicine Ltd.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30202 - Endocrinology and metabolism (including diabetes, hormones)
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2020
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Pharmacogenomics
ISSN
1462-2416
e-ISSN
—
Volume of the periodical
21
Issue of the periodical within the volume
5
Country of publishing house
GB - UNITED KINGDOM
Number of pages
7
Pages from-to
317-323
UT code for WoS article
000539318400003
EID of the result in the Scopus database
2-s2.0-85084294316